AU2001257362A1 - The use of tolerogenic dendritic cells for enhancing tolerogenicity in a host and methods for making the same - Google Patents

The use of tolerogenic dendritic cells for enhancing tolerogenicity in a host and methods for making the same

Info

Publication number
AU2001257362A1
AU2001257362A1 AU2001257362A AU5736201A AU2001257362A1 AU 2001257362 A1 AU2001257362 A1 AU 2001257362A1 AU 2001257362 A AU2001257362 A AU 2001257362A AU 5736201 A AU5736201 A AU 5736201A AU 2001257362 A1 AU2001257362 A1 AU 2001257362A1
Authority
AU
Australia
Prior art keywords
host
making
methods
same
dendritic cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001257362A
Inventor
Nick Giannoukakis
Lina Lu
Paul D Robbins
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pittsburgh
Original Assignee
University of Pittsburgh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Pittsburgh filed Critical University of Pittsburgh
Publication of AU2001257362A1 publication Critical patent/AU2001257362A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4637—Other peptides or polypeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/46433—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/15—Transforming growth factor beta (TGF-β)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
AU2001257362A 2000-04-28 2001-04-27 The use of tolerogenic dendritic cells for enhancing tolerogenicity in a host and methods for making the same Abandoned AU2001257362A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20047900P 2000-04-28 2000-04-28
US60200479 2000-04-28
PCT/US2001/013661 WO2001083713A2 (en) 2000-04-28 2001-04-27 The use of tolerogenic dendritic cells for enhancing tolerogenicity in a host and methods for making the same

Publications (1)

Publication Number Publication Date
AU2001257362A1 true AU2001257362A1 (en) 2001-11-12

Family

ID=22741897

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001257362A Abandoned AU2001257362A1 (en) 2000-04-28 2001-04-27 The use of tolerogenic dendritic cells for enhancing tolerogenicity in a host and methods for making the same

Country Status (3)

Country Link
US (1) US6936468B2 (en)
AU (1) AU2001257362A1 (en)
WO (1) WO2001083713A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040072726A1 (en) 2002-02-01 2004-04-15 Ryuichi Morishita Decoy-containing pharmaceutical compositions and method of using the same
WO2003073916A2 (en) * 2002-03-01 2003-09-12 The General Hospital Corporation Immune regulation
GB0207440D0 (en) * 2002-03-28 2002-05-08 Ppl Therapeutics Scotland Ltd Tolerogenic antigen-presenting cells
CA2388441A1 (en) * 2002-06-10 2003-12-10 Wei-Ping Min Immunomodulation using rna interference
WO2005004913A1 (en) * 2003-07-09 2005-01-20 Anges Mg, Inc. Pharmaceutical composition containing decoy and method of using the same
US7625721B2 (en) * 2004-02-03 2009-12-01 Polymer Technology Systems, Inc. Non-precipitating bodily fluid analysis system
EP1814981A4 (en) * 2004-10-25 2009-09-30 Baylor Res Inst Dendritic cells loaded with heat shocked melanoma cell bodies
US8138160B2 (en) * 2006-08-03 2012-03-20 Warsaw Orthopedic, Inc. Reagents, methods and systems to suppress pro-inflammatory cytokines
CN102099054A (en) * 2008-06-06 2011-06-15 贝勒研究院 Respiratory syncytial virus renders dendritic cells tolerogenic
US20120022113A1 (en) * 2009-01-21 2012-01-26 Aldridge Jr Jerry R Methods for suppressing tipdc trafficking or accumulation and preventing hypercytokinemia
WO2015048395A1 (en) * 2013-09-26 2015-04-02 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Tolerogenic dendritic cells to treat inflammatory bowel disease
AU2014348184B2 (en) * 2013-11-18 2020-08-27 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Microsphere-based delivery and ex vivo manipulation of dendritic cells for autoimmune therapies
US20170151281A1 (en) 2015-02-19 2017-06-01 Batu Biologics, Inc. Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer
CA3197423A1 (en) 2020-11-04 2022-05-12 Daniel Getts Engineered chimeric fusion protein compositions and methods of use thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5958403A (en) * 1992-02-28 1999-09-28 Beth Israel Hospital Association Methods and compounds for prevention of graft rejection
US6498147B2 (en) * 1992-05-22 2002-12-24 The Scripps Research Institute Suppression of nuclear factor-κb dependent processes using oligonucleotides
US5871728A (en) * 1995-03-31 1999-02-16 University Of Pittsburgh Method of regulating dendritic cell maturation

Also Published As

Publication number Publication date
WO2001083713A2 (en) 2001-11-08
WO2001083713A3 (en) 2002-03-14
US6936468B2 (en) 2005-08-30
US20020048564A1 (en) 2002-04-25

Similar Documents

Publication Publication Date Title
AU2002225681A1 (en) Yeast-dentritic cell vaccines and uses thereof
AU2001250957A1 (en) Integrated capacitor-like battery and associated method
AU2002225356A1 (en) Glucopyranosyloxypyrazole derivatives and use thereof in medicines
AU2640099A (en) Structure member excellent in water-repellency and manufacturing method thereof
AU2002231052A1 (en) Technical standard review and approval
AU2002322211A1 (en) Methods and compisitions for activation human t cells in vitro
AU2001267181A1 (en) Polyubiquitin based hydrogel and uses thereof
AU2001257362A1 (en) The use of tolerogenic dendritic cells for enhancing tolerogenicity in a host and methods for making the same
AU2001248751A1 (en) Compositions disintegrating in oral cavity and preparations disintegrating in oral cavity
AU2003237416A1 (en) Novel tolerogenic dendritic cells and therapeutic uses therefor
AU6002800A (en) Improvements in and relating to portable disc holders
AU2001229439A1 (en) Bioconjugates and uses thereof
AU2002252073A1 (en) Tolerogenic antigen presenting cells and in treating immune-inflammatory conditions
AU2002346446A1 (en) Methods and compositions in checkpoint signaling
AU2001271536A1 (en) Adenylyl and guanylyl cyclases
AUPR751101A0 (en) Density and level gauges
AU2001252062A1 (en) Steatosis-modulating factors and uses thereof
AUPR968801A0 (en) Improvements in enzyme stability
AU3997099A (en) Business card in the form of a cd-rom
EP1578938A3 (en) Promotion of peroxisomal catalase function in cells
AU2001231917A1 (en) Isolated complex comprising a nnt-1 protein and in addition at least a clf-1 protein and/or a scntfralpha protein
AU2001254976A1 (en) Electrochemical methods and cells
AU2002338561A1 (en) Lipid producing cells and uses thereof
AU2001269106A1 (en) Novel alpha expressed in heart and testis
AU2002238794A1 (en) Methods and compositions involved in groucho-mediated differentiation